Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
FL

WKN: A2PJ4S | ISIN: DK0061123312 | Ticker: 96X
Frankfurt
18.11.26 | 15:25
2,490 Euro
-0,40 % -0,010
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
FLUOGUIDE A/S Chart 1 Jahr
5-Tage-Chart
FLUOGUIDE A/S 5-Tage-Chart

Aktuelle News zur FLUOGUIDE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.10.FluoGuide A/S Invites Investors to Q3 Webcast - Clinical Progress and the Road Ahead297KØBENHAVN, DK / ACCESS Newswire / October 23, 2026 / FluoGuide A/S (STO:FLUO) - FluoGuide A/S will publish its interim report for Q3 2026 on Thursday, 26 November 2026, followed by a live investor webcast...
► Artikel lesen
05.10.FluoGuide A/S: FluoGuide Enrolls First Patient in U.S. Phase 2 Trial of FG001 in High-Grade Glioma312KØBENHAVN, DK / ACCESS Newswire / October 5, 2026 / FluoGuide A/S (STO:FLUO) - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotechnology company focused on precision cancer surgery...
► Artikel lesen
02.10.FluoGuide A/S: FluoGuide Enters Collaboration with Leica Microsystems, a World Leading Medical Technology Company718KØBENHAVN, DK / ACCESS Newswire / October 2, 2026 / FluoGuide A/S (STO:FLUO) FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces a collaboration...
► Artikel lesen
25.08.Earnings Call Transkript: FluoGuide treibt US-Krebsstudie im ersten Halbjahr 2026 voran1
25.08.FluoGuide A/S Q2 Loss Increases2
25.08.FluoGuide A/S Publishes Interim Report for Q2 2026386KØBENHAVN, DK / ACCESS Newswire / August 25, 2026 / Fluoguide A/S (STO:FLUO) ("FluoGuide" or the "Company") today releases its results for the period 1 January 2026 - 30 June 2026. The Q2 report is...
► Artikel lesen
FLUOGUIDE Aktie jetzt für 0€ handeln
12.08.Invitation to FluoGuide A/S Live Webcast on 25 August 2026351COPENHAGEN, DK / ACCESS Newswire / August 12, 2026 / FluoGuide A/S (STO:FLUO) will publish its interim report for Q2 2026 on Tuesday, 25 August 2026.Later that day, CEO Morten Albrechtsen and CFO Ole...
► Artikel lesen
01.07.FluoGuide A/S: Update on 2026 Outlook and Company Progress495COPENHAGEN, DK / ACCESS Newswire / July 1, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO), a clinical-stage biotech company focused on precision cancer surgery, is pleased to share an...
► Artikel lesen
29.06.FluoGuide A/S: FluoGuide Announces Positive Results from Phase 2 Oral, Head and Neck Cancer Trial454COPENHAGEN, DK / ACCESS Newswire / June 29, 2026 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced...
► Artikel lesen
27.05.FluoGuide A/S Publishes Interim Report for Q1 2026480KØBENHAVN, DK / ACCESS Newswire / May 27, 2026 / Fluoguide A/S (STO:FLUO) ("FluoGuide" or the "Company") today releases its results for the period 1 January 2026 - 31 March 2026. The Q1 report is available...
► Artikel lesen
13.05.Invitation to FluoGuide A/S Live Webcast on 27 May 2026395KØBENHAVN, DK / ACCESS Newswire / May 13, 2026 / FluoGuide A/S (STO:FLUO) will publish its interim report for Q1 2026 on Wednesday, 27 May 2026.Later that day, CEO Morten Albrechtsen and CFO Ole Larsen...
► Artikel lesen
10.04.FluoGuide A/S: Positive interim results from an investigator-initiated study of FG001 in meningioma and low-grade glioma surgery, re-presented at SNOG291Copenhagen, Denmark, 10 April 2026 - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company maximizing surgical outcomes in oncology by lighting up cancer. The interim data from...
► Artikel lesen
25.03.Minutes from Annual General Meeting in FluoGuide A/S597COPENHAGEN, DENMARK / ACCESS Newswire / March 25, 2026 / FluoGuide A/S (STO:FLUO)("FluoGuide" or the "Company") held its annual general meeting on 25 March 2026.To the shareholders of FluoGuide A/S.The...
► Artikel lesen
18.03.FluoGuide A/S: FluoGuide Receives FDA Fast Track Designation for FG001 in High-Grade Glioma437COPENHAGEN, DENMARK / ACCESS Newswire / March 18, 2026 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, announces...
► Artikel lesen
10.03.Notice of Annual General Meeting in FluoGuide A/S550KØBENHAVN, DENMARK / ACCESS Newswire / March 10, 2026 / FluoGuide A/S (STO:FLUO)The board of directors hereby convenes the Annual General Meeting of FluoGuide A/S, company registration (CVR) no. 39...
► Artikel lesen
25.02.FluoGuide A/S Publishes Annual Report For The Fiscal Year 2025704COPENHAGEN, DK / ACCESS Newswire / February 25, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO) hereby publishes its annual report for the fiscal year 2025. The annual report, including...
► Artikel lesen
25.02.FluoGuide A/S Publishes Interim Report For Q4 2025438COPENHAGEN, DK / ACCESS Newswire / February 25, 2026 / Fluoguide A/S ("FluoGuide" or the "Company")(STO:FLUO) today releases its results for the period 1 January 2025 - 31 December 2025. The Q4 report...
► Artikel lesen
20.02.FluoGuide A/S: FDA Clears FluoGuide's IND for FG001 in High-Grade Glioma; U.S. Clinical Trial Remains on Track821COPENHAGEN, DENMARK / ACCESS Newswire / February 20, 2026 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company maximizing surgical outcomes in oncology by lighting up cancer...
► Artikel lesen
19.02.Invitation to FluoGuide A/S Live Webcast on 25 February 2026345KØBENHAVN, DK / ACCESS Newswire / February 19, 2026 / FluoGuide A/S (STO:FLUO) will publish its Annual Report 2025 on Wednesday, 25 February 2026.Later that day, CEO Morten Albrechtsen and CFO Ole Larsen...
► Artikel lesen
21.01.FluoGuide A/S: FluoGuide Submits an IND for FG001, to Initiate First U.S. Registration Trial399KØBENHAVN, DK / ACCESS Newswire / January 21, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced...
► Artikel lesen
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1